Drugs and patents in ATC class N01AH

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
FENTANYL CITRATE AND DROPERIDOL	droperidol; fentanyl citrate
INNOVAR	droperidol; fentanyl citrate
DURAGESIC-100	fentanyl
DURAGESIC-12	fentanyl
DURAGESIC-25	fentanyl
>Tradename	>Generic Name

Last updated: June 13, 2026

ATC class N01AH (opioid anesthetics) is dominated by injectable opioid analgesics used for perioperative anesthesia and sedation. Patent estates are concentrated around (1) originator formulations (salt forms, concentrations, buffered vehicles, and solubilizers), (2) controlled-release or long-duration delivery technologies, and (3) indications and dosing regimens. Generic entry risk hinges on whether products are truly “same active ingredient, same salt, same strength, same route” and whether Orange Book-listed formulation or method patents block FDA approval for generics via Paragraph IV.

H1: Market Dynamics and Patent Landscape for ATC N01AH Opioid Anesthetics (FDA Exclusivity, Patent Expiration, and Generic Entry Risk)

Which opioid anesthetics define ATC N01AH and how do they compete in perioperative care?

ATC N01AH spans opioid agonists used for anesthesia-related pain control, typically as IV bolus dosing, infusion, or short-acting perioperative administration. Market share is shaped by hospital formularies, anesthesiology standard-of-care protocols, and product usability in the OR (concentration, stability, onset, and dosing flexibility).

Core commercial anchors within N01AH

The class is typically led by widely adopted perioperative opioids, with competitive positioning by route and formulation rather than by clinical differentiation. The commercial “winner” tends to be the least operationally burdensome product with the broadest formulary acceptance.

High-impact market dynamics

Switching costs are low at the molecule level but higher at the formulation and concentration level, because pharmacy and anesthesia workflows standardize specific presentations.
Tendering drives price compression once patents or exclusivity lift.
Inventory and stability matter because anesthesia departments standardize draw-up and infusion workflows.
Controlled substances controls availability and can slow rapid substitution even when legal barriers fall away.

How supply chain and procurement affect pricing post-generic entry

When generics gain formulary traction, price usually compresses in parallel with volume growth because anesthesia departments buy at scale through group purchasing organizations.
Distributors may shift allocation toward higher-margin SKUs for originators or authorized generics, slowing true pricing normalization.

Competitive landscape: what actually differentiates products

In N01AH, differentiation is usually:

Pharmacotechnical: buffered pH, solubilizer systems, co-solvents, osmolality constraints.
Usability: single-dose vs multi-dose vials, dilution flexibility, infusion compatibility.
Regulatory posture: whether additional indications expand perioperative use and whether label language ties to specific dosing regimens.

What patents protect opioid anesthetics in ATC N01AH and how are they structured?

Patent estates for opioid anesthetics typically cluster into three buckets: composition (salt/vehicle), formulation (stabilization and solubilizers), and use (method of administration, dosing regimens). Many modern estates also include manufacturing-process claims.

Patent estate architecture (typical for perioperative injectables)

Active ingredient and salt form
- Claims covering specific salt forms, hydrates/solvates, and purity specifications.
Formulation and vehicle
- Buffer systems, surfactant/co-solvent systems, antioxidants, and concentration-specific stabilization.
Method-of-use
- Regimens such as perioperative administration timing, titration algorithms, or anesthesia induction patterns.
Manufacturing process
- Steps that achieve stability, particle size control, sterilization parameters, or purification methods.

What to look for on the patent record

When screening for generics, the key is whether the reference listed drug (RLD) has:

Orange Book “listed” formulation patents that cover composition-by-vehicle or concentration.
Method-of-use patents tied to label language or operational dosing.
Multiple blocking patents across different patent families.

Geographic coverage patterns

US: Orange Book governs FDA generic eligibility via Hatch-Waxman.
EU/UK: patent enforceability and regulatory data protection affect substitution and launch timing.
Canada and other markets: Orange Book analogs exist but differ in listing requirements; patent litigation timing tends to drive entry more than regulatory exclusivity alone.

How long is exclusivity for opioid anesthetics in N01AH, and when does exclusivity end?

Exclusivity for opioid anesthetics splits into:

Patent exclusivity (listed patents expiring on specific dates)
Regulatory exclusivity (data exclusivity for new molecular entities and 505(b)(2 exclusivity, where applicable)

Featured snippet answer

Exclusivity ends when the last blocking Orange Book patent expires or when a paragraph IV challenge leads to early settlement or a favorable court ruling. Any residual non-infringed or non-listed patents may still restrict “at-risk” launches even when exclusivity ends.

Timelines that matter for entry planning

Patent expiration date: last day a blocking patent can prevent generic approval.
Hatch-Waxman 30-month stay: governs if a Paragraph IV generic is launched “at risk” pending litigation.
Pediatric exclusivity (if any): can extend certain US patent protections by 6 months tied to a qualifying development program.
50-state tender cycles: can shift practical uptake by months after the legal date.

What Orange Book status applies to ATC N01AH opioids, and which patents are typically listed?

Orange Book status is decisive for US generic entry. For injectable opioids, the most frequent listing patterns are:

Drug product formulation patents
Method-of-use patents
Manufacturing process patents
Sometimes formulation concentration-specific patents

How to interpret listing risk

A generic must address each Orange Book-listed patent tied to the RLD.
If a listed patent claims a formulation element that the generic cannot easily design around, the generic either waits for expiration or files Paragraph IV with litigation risk.

Common listing “hotspots” for perioperative opioids

Concentration-specific stabilization
Vehicle pH and buffer
Solubilizer and preservative system
Container closure compatibility that supports shelf-life and sterility assurance

Which opioid anesthetic patents are challenged via Paragraph IV, and what outcomes drive launches?

Paragraph IV challenges determine when generic applicants can enter “earlier” than patent expiration. Outcomes typically fall into:

Settlement: authorized generic (AG) or delayed launch date is paid for.
Court decision: either infringement confirmation blocks entry or non-infringement/invalidity enables launch.
No settlement: entry occurs only after final adjudication or expiration.

What makes N01AH cases litigable

Injectable opioid formulations often have multiple overlapping patent families, including formulation and manufacturing steps that are hard to fully avoid without redesigning product and process.
Method-of-use patents can be more difficult to design around if generic label mirrors originator instructions.

Litigation lever points for both sides

Originators:

Seek injunctions tied to infringement and leverage settlement to preserve market share. Generics:
Attack validity (obviousness, lack of enablement) and non-infringement through formulation redesign and labeling carve-outs.

How many patents cover key opioid anesthetic products and what does the “blocking set” look like?

The number of patents can be large because formulation and process patents stack within the same family and across related continuations. Practically, the “blocking set” is the subset of Orange Book-listed patents that a generic must address to get approval and avoid legal injunction risk.

Screening framework for blocking patents

Count listed patents per RLD and group by family.
Identify which listed patents are formulation vs method vs process.
Focus on those with the latest expiration dates and those most central to the generic’s need to copy formulation and/or labeling.

What formulation patents are most likely to block generic opioids in N01AH?

Formulation patents are typically the main barrier for injectables because generics must match the RLD at the product-quality and performance level to satisfy bioequivalence and product sameness.

High-risk formulation claim themes

Buffer composition and pH range
Solubilizers and co-solvents at specific ratios
Surfactant systems used to maintain clarity and prevent precipitation
Antioxidants/preservatives tied to stability and shelf-life
Compatibility with container systems that prevent leachables or degradation

Design-around reality

Swapping excipients can introduce bioequivalence and stability challenges and can trigger additional clinical and CMC burdens.
Even if a formulation is technically distinct, Orange Book “sameness” tests can still treat it as infringing if claims are broad.

Do method-of-use patents block opioid anesthetic generics, and how do label carve-outs work?

Method-of-use patents can block approval if the generic’s proposed label practice infringes. Label carve-outs can sometimes avoid infringement but require careful claim-to-label mapping.

Typical infringement pattern

If a method-of-use patent covers a dosing regimen that the generic’s label mirrors, the generic may face injunction risk.
If the patent requires a specific timing/dosing pattern that the label cannot include without infringement, the generic must carve out.

Operational constraints in hospitals

Even if a generic label has carve-outs, in-practice substitution can still happen through off-label use. However, for Hatch-Waxman approval and injunction risk, the controlling issue remains whether the approved label infringes.

Which companies are the main originators and generic challengers in opioid anesthetics?

In N01AH, major originators are diversified pharma and specialty injectables manufacturers. Generic challengers usually include large generic developers and injectable specialists that focus on complex formulation equivalency.

Competitive map by launch archetype

Originator defense: settlement strategy, lifecycle management through reformulations, and broad composition/process coverage.
Generic strategy: Paragraph IV for listed patents with a plan to launch via design-around if successful; alternatively, pursue authorized generics as settlement outcomes.

What patent litigation affects opioid anesthetics in ATC N01AH and how do settlements change market entry?

Patent litigation is the primary driver of launch timing for injectables once Paragraph IV is filed. Settlements often include:

Generic delay (fixed dates)
Authorized generic supply to originator’s preferred channels
“No design-around” covenants where the settlement restricts future entry strategies

How to interpret litigation impact for market planning

A court decision can accelerate generic entry by invalidating key patents.
A settlement can preserve originator revenue longer than predicted by single-patent expiration dates.
Even with an expired patent, lingering non-expired formulation patents can block approval.

What FDA regulatory status and approval pathways apply to opioid anesthetics in N01AH?

Most opioid anesthetic injectables are approved as:

505(b)(1) for originators,
505(b)(2) for modified formulations or label changes, and
505(j) for generics via ANDA referencing the RLD.

Where data exclusivity matters

Data exclusivity primarily affects launches of 505(b)(2 products and can slow certain reformulation pathways. For generics, the key barrier is Orange Book patents rather than regulatory exclusivity.

Stability and CMC for injectables

Injectable opioid generics must clear:

Sterility and container closure performance
Particle control and clarity specifications
Shelf-life stability at intended storage
Manufacturing controls for consistent impurities

How does ATC Class N01AH compare with other opioid analgesics in patent risk and market entry?

N01AH injectables face higher formulation and CMC scrutiny than many oral opioid forms, and opioid supply chain constraints can magnify the practical impact of legal status.

Key differences versus non-anesthetic opioid categories

Injectable products have tighter formulation sameness and stability constraints.
Anesthesia workflow standardization makes product presentation a competitive lever.
Perioperative indications can increase dependence on method-of-use labeling.

Generic entry scenarios: what happens when the last blocking patent expires?

When the latest blocking patent expires:

ANDA approval can become effective only if the applicant has addressed all Orange Book patents (including those expiring later).
If there are concurrent non-listed patents, a launch can still face litigation, but injunction risk is reduced for approvals that do not infringe listed blocking patents.

Scenario-based planning outcomes

Uncontested expiration
- Generic(s) launch quickly, price drops, originator market share declines.
Post-expiration continued litigation
- Some firms launch “at risk,” accepting potential damages rather than injunction.
Settlement prior to expiration
- Launch occurs on the agreed date, often with authorized generic maintained.

Key takeaways

ATC N01AH opioid anesthetics are governed by injectable formulation realities and an Orange Book-centric patent landscape where formulation and method-of-use patents are the main blocking set.
Market entry timing usually follows the latest blocking Orange Book patent expiration date, but Paragraph IV litigation and settlements can shift practical launches by 6 to 30 months or longer.
Product differentiation in this class is typically not clinical novelty but formulation usability (concentration, pH/buffer, solubilizers, stability) and label-defined dosing.

FAQs

What drives fastest generic uptake of injectable opioid anesthetics, patent expiration or formulary tendering?
Do authorized generics materially change price erosion after Paragraph IV settlements in opioid injectables?
How do formulation design-arounds typically work for buffered or solubilized injectable opioids under Orange Book scrutiny?
Which patent types (formulation vs method-of-use vs process) most often survive challenges in opioid anesthetic ANDA litigation?
How does container closure compatibility and stability CMC affect whether generics can copy opioid injectable performance despite patent design-arounds?

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. Regulatory Exclusivity Information. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-regulatory-exclusivity
35 U.S.C. § 271(e) (infringement of patents in the context of FDA submissions). Cornell Law School. https://www.law.cornell.edu/uscode/text/35/271
21 U.S.C. § 355(j) (Hatch-Waxman ANDA and Paragraph IV framework). Cornell Law School. https://www.law.cornell.edu/uscode/text/21/355